Dr. Somer on Hesitancy Regarding Biosimilar Use in Oncology
November 15th 2019Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.
Read More
Dr. Somer on Optimal Combinations in mRCC
March 27th 2019Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.
Read More
Dr. Somer on Treatment Selection Considerations in RCC
January 8th 2019Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).
Read More
Dr. Somer on Immunotherapy Combinations in mRCC
December 8th 2018Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.
Read More